1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Autotelic Lab to present at AACC 2012

Autotelic Lab will be presenting data on its platform of expanded range point-of-care diagnostic devices

FOR IMMEDIATE RELEASE

 
autoteliclab_logo_4
autoteliclab_logo_4
PRLog (Press Release) - Jul. 2, 2012 - Autotelic Lab, Fountain Valley, a developer of quantitative rapid tests, announced today that it will be presenting at AACC 2012―Expanded Range Point-of-Care Therapeutic Drug Monitoring (TDM) assay for FSH.  IVF has a delivery rate per started cycle of around 22% and close to 250,000 children where 26% of pregnancies were twins and 2.5% triplets.  
IVF Protocols—with a target of generating between 8 and 15 oocytes—are complex, time consuming, expensive and may give rise to considerable patient discomfort and increased chance of complications, especially the Ovarian Hyperstimulation Syndrome (OHSS) and possible long term side effects such as increased cancer risk.  Ovarian epithelial cancer is more common in individuals with elevated Gonadotropin-releasing hormones (GnRH) including  Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) such as postmenopausal women or women who have received treatment to induce ovulation (e.g. FSH treatment).  FSH regulates gene expression in ovarian tumors and causes neovascularization of ovarian cancers by increasing Vascular Endothelial Growth Factor (VEGF) expression through upregulation of Survivin.  To facilitate individualized treatment regimens that would reduce the cost of medication and adverse risks such as cancer and OHSS, we have developed point-of-care therapeutic drug monitoring of the gonadotropins widely used in IVF, namely FSH, LH, and hCG.  The potential of FSH device as a diagnostic tool for ovarian cancer will be discussed.

Herein, Dr. Kouros Motamed and colleagues describe the development of rapid point-of-care tests for detection of FSH using the expanded range platform alleviating the needs for complicated dilutions and repeats making it truly a point-of-care test.  Traditional immunoassay for FSH exhibits at best two logs of dynamic range (1-100 IU/L); whereas, our FSH assay exhibits at least 4 logs of dynamic range (1-10,000 IU/L). As such, these tests would allow for more effective screening for ovarian cancer as well as therapeutic drug monitoring of FSH. These findings will be presented at American Association for Clinical Chemistry Annual Meeting (AACC), July 15-19th, 2012, Los Angeles, CA, USA.

Abstract # D-70: Expanded Range Point-of-Care Therapeutic Drug Monitoring (TDM
assay for FSH. Kouros Motamed, Larn Hwang, Chao Hsiao, Vuong Trieu.  Tuesday, July 17, 2:00 pm – 4:30 pm Point-of-Care Testing.

About AACC:

AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and related disciplines. Founded in 1948, the society has over 8,000 members and is headquartered in Washington, DC. AACC vision is to provide leadership in advancing the practice and profession of clinical laboratory science and its application to health care. AACC annual meeting is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries.

About Autotelic Lab:


Autotelic lab is a provider of quantitative point-of-care testing solutions including quantitative lateral flow cassettes, lateral flow reader, as well as a quantification service.  Our product lines include emergency care, women's health, cancer biomarkers, and regenerative medicine.  Our offerings are uniquely configured to accept multiple readers to satisfy all possible field conditions; from highly specialized requiring specificity and sensitivity to low tech without access to normal laboratory resources.  Our mission is to put testing into the hands of primary care providers and patients.   These tests are simple to use and require no specialized equipment or trained personnel.  They are rapid with results within 20 minutes of blood collection.  They are convenient and can be deployed at home, in doctor’s office, in emergency rooms, or in centralized laboratories. Moreover, they are quantitative with a linear response range similar to tests performed at centralized laboratories.  

These proprietary diagnostic devices deployed at point-of-care are being used for therapeutic drug monitoring by our partner―Biomiga Diagnostics― to personalize dosing of wide range of therapeutics e.g., chemotherapy and follicle hormone therapy (http://www.biomigadiagnostics.com).  

The executives of Autotelic Lab are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing.  With more than a decade of drug development experience, the leadership team has expertise ranging from basic/applied research, preclinical/clinical development, pharmacokinetics/pharmacodynamics biomarker development, mobile technology, regulatory, legal, marketing and business development. http://www.autoteliclab.com


Kouros Motamed, Ph.D.
Chief Executive Officer
kmotamed@autoteliclab.com

Photo:
http://www.prlog.org/11914267/1

--- End ---

Click to Share

Contact Email:
***@auteliclab.com
Source:Autotelic Lab
Phone:714-445-0127
Zip:92708
City/Town:Fountain Valley - California - United States
Industry:Biotech, Health, Medical
Tags:point of care, fsh, follicle stimulating hormone, rapid test, women s health, ivf, cancer, ovarian cancer, diagnostics
Shortcut:prlog.org/11914267
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share